Boron uptake in normal melanocytes and melanoma cells and boron biodistribution study in mice bearing B16F10 melanoma for boron neutron capture therapy

Autor(es)

Faiao-Flores, Fernanda ^{[1, 2]} ; Pinto Coelho, Paulo Rogerio ^[3] ; Toledo Arruda-Neto, Joao Dias ^{[4, 5]} ; Pires Camillo, Maria Aparecida ^[3] ; Maria-Engler, Silvya Stuchi ^[6] ; Grassi Rici, Rose Eli ^[7] ; Souza Sarkis, Jorge Eduardo ^[3] ; Maria, Durvanei Augusto ^[2]

Afiliação do(s) autor(es)

^[1] Univ Sao Paulo, Fac Med, Sao Paulo - Brazil

^[2] Butantan Inst, Biochem & Biophys Lab, BR-05503900 Sao Paulo - Brazil

^[3] Inst Nucl & Energy Res, Sao Paulo - Brazil

^[4] Univ Sao Paulo, Inst Phys, Sao Paulo - Brazil

^[5] CEPESq UniItalo Italy Brazilian Univ Ctr, Sao Paulo - Brazil

^[6] Univ Sao Paulo, Sch Pharmaceut Sci, Dept Clin Chem & Toxicol, Sao Paulo - Brazil

^[7] Univ Sao Paulo, Dept Surg, Fac Vet Med & Zootechny, Sao Paulo - Brazil

• Tipo de documento: Artigo Científico
• Fonte: RADIATION AND ENVIRONMENTAL BIOPHYSICS; v. 51, n. 3, p. 319-329, AUG 2012.
• Citações Web of Science: 4

Resumo

Information on B-10 distribution in normal tissues is crucial to any further development of boron neutron capture therapy (BNCT). The goal of this study was to investigate the in vitro and in vivo boron biodistribution in B16F10 murine melanoma and normal tissues as a model for human melanoma treatment by a simple and rapid colorimetric method, which was validated by HR-ICP-MS. The B16F10 melanoma cell line showed higher melanin content than human melanocytes, demonstrating a greater potential for boronophenylalanine uptake. The melanocytes showed a moderate viability decrease in the first few minutes after BNCT application, stabilizing after 75 min, whereas the B16F10 melanoma showed the greatest intracellular boron concentration at 150 min after application, indicating a different boron uptake of melanoma cells compared to normal melanocytes. Moreover, at this time, the increase in boron uptake in melanoma cells was approximately 1.6 times higher than that in normal melanocytes. The B-10 concentration in the blood of mice bearing B16F10 melanoma increased until 90 min after BNCT application and then decreased after 120 min, and remained low until the 240th minute. On the other hand, the B-10 concentration in tumors was increased from 90 min and maximal at 150 min after application, thus confirming the in vitro results. Therefore, the present in vitro and in vivo study of B-10 uptake in normal and tumor cells revealed important data that could enable BNCT to be possibly used as a treatment for melanoma, a chemoresistant cancer associated with high mortality. (AU)

• Processo FAPESP: 08/58817-4 - Geração de peles artificiais humanas e melanomas invasivos como plataforma para testes farmacológicos
• Beneficiário: Silvya Stuchi Maria-Engler
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 08/56397-8 - Avaliação da atividade antitumoral do composto sintético DM-1 e terapia de captação de nêutrons por boro (BNCT) associados ao quimioterápico dacarbazina no tratamento do melanoma
• Beneficiário: FERNANDA FAIÃO FLORES
• Modalidade de apoio: Bolsas no Brasil - Doutorado Direto